摘要: |
[摘要] 白介素(IL)-37b是最近才被命名的白介素-1家族新成员,具有强大的抗炎作用。研究发现,动脉粥样硬化性疾病患者循环和斑块内IL-37b表达显著升高,与预后密切相关。动物实验表明,无论是内源性还是外源性IL-37b都具有显著的抗动脉粥样硬化作用。IL-37b可能成为动脉粥样硬化性疾病防治的新靶点。 |
关键词: 白介素-37b 炎症 动脉粥样硬化 |
DOI:10.3969/j.issn.1674-3806.2019.05.02 |
分类号:R 543.5 |
基金项目:国家自然科学基金资助项目(编号:81560085) |
|
IL-37b and atherosclerosis: from bench to bedside |
JI Qing-wei
|
Emergency & Critical Care Center, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing 100029, China
|
Abstract: |
[Abstract] Interleukin-37b(IL-37b) is a novel anti-inflammatory cytokine in the interleukin-1 ligand family. Accumulating evidence has demonstrated that both circulating and local IL-37b levels are increased in the patients with atherosclerotic disease and associated with an adverse outcome, and some experimental studies have showed that both exogenous IL-37b and endogenous IL-37b protect mice from atherosclerosis, which indicates that IL-37b may be a novel therapeutic target in prevention and treatment of atherosclerotic disease. |
Key words: Interleukin-37b(IL-37b) Inflammation Atherosclerosis |